Pituitary adenoma
For patient information click here
| Pituitary adenoma | |
 | |
|---|---|
| ICD-10 | D35.2 |
| ICD-9 | 237.0 |
| ICD-O: | Template:ICDO |
| MeSH | D010911 |
|
WikiDoc Resources for Pituitary adenoma |
|
Articles |
|---|
|
Most recent articles on Pituitary adenoma Most cited articles on Pituitary adenoma |
|
Media |
|
Powerpoint slides on Pituitary adenoma |
|
Evidence Based Medicine |
|
Cochrane Collaboration on Pituitary adenoma |
|
Clinical Trials |
|
Ongoing Trials on Pituitary adenoma at Clinical Trials.gov Trial results on Pituitary adenoma Clinical Trials on Pituitary adenoma at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Pituitary adenoma NICE Guidance on Pituitary adenoma
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Pituitary adenoma Discussion groups on Pituitary adenoma Patient Handouts on Pituitary adenoma Directions to Hospitals Treating Pituitary adenoma Risk calculators and risk factors for Pituitary adenoma
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Pituitary adenoma |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
Pituitary tumors were, historically, classed as basophilic, acidophilic, or chromophobic on the basis of whether or not they took up the stains hematoxylin and eosin. This classification has fallen into disuse, in favor of a classification based on what type of hormone is secreted by the tumor (though tumors which do not secrete any active hormone ("non-functioning tumors") are still sometimes called "chromophobic"). At present, classification of pituitary tumors is based on plasma hormone levels or immunohistochemical staining:
| Type of adenoma | Secretion | Staining | Pathology |
| corticotrophic adenomas | secrete adrenocorticotropic hormone (ACTH) and pro-opiomelanocortin (POMC) | basophilic | Cushing's disease |
| somatotrophic adenomas | secrete growth hormone (GH) | acidophilic | acromegaly (gigantism) |
| thyrotrophic adenomas (rare) | secrete thyroid-stimulating hormone (TSH) | basophilic | occasionally hyperthyroidism[2], usually doesn't cause symptoms |
| gonadotrophic adenomas | secrete luteinizing hormone (LH), follicle-stimulating hormone (FSH) and their subunits | basophilic | usually doesn't cause symptoms |
| lactrotrophic adenomas or prolactinomas (most common) | secrete prolactin | acidophilic | galactorrhea, hypogonadism, amenorrhea, infertility, and impotence |
| null cell adenomas | do not secrete hormones | may stain positive for synaptophysin |
Diagnosis
The diagnosis is generally entertained either on the basis of visual difficulties arising from the compression of the optic nerve by the tumor, or on the basis of manifestations of excess hormone secretion: the specifics depend on the type of hormone. The specific area of the visual pathway at which compression by these tumours occurs is at the optic chiasma.
The anatomy of this structure causes pressure on it to produce a defect in the temporal visual field on both sides, a condition called bitemporal hemianopia.
Tumors which cause visual difficulty are likely to be macroadenomata greater than 10 mm in diameter; tumors less than 10 mm are microadenomata.
Some tumors secrete more than one hormone, the most common combination being GH and prolactin.
Prolactinomas are frequently diagnosed during pregnancy, when the hormone progesterone increases the tumor's growth rate. Headaches may be present. The diagnosis is confirmed by testing hormone levels, and by radiographic imaging of the pituitary (for example, by CT scan or MRI).
Treatment
Treatment options depend on the type of tumor and on its size:
- Prolactinomas are most often treated with bromocriptine or more recently, cabergoline which, unlike bromocriptine, decreases tumor size as well as alleviates symptoms, both dopamine agonists, and followed by serial imaging to detect any increase in size. Treatment where the tumor is large can be with radiation therapy or surgery, and patients generally respond well. Efforts have been made to use a progesterone antagonist for the treatment of prolactinomas, but so far have not proved successful.
- Thyrotrophic adenomas respond to octreotide, a long-acting somatostatin analog, in many but not all cases according to a review of the medical literature. Unlike prolactinomas, thyrotrophic adenomas characteristically respond poorly to dopamine agonist treatment.Template:Ref label
References
- ^ Template:Note label Chanson, Philippe; Weintraub, Bruce D.; and Harris, Alan G. (1993) Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomata. Annals of Internal Medicine 119 (3), 236-240.
See Also
External links
- Cancer.gov: pituitary tumors
- Case report of Bilateral Hemianopsia Due to Pituitary Adenoma. Clinical Cases and Images.
- Medical Illustration of Pituitary Adenomas by Frank H. Netter
cs:Adenom hypofýzy nl:Hypofysetumor sk:Adenóm hypofýzy sv:Hypofystumör